TP53 and neoplasm: In the current study, we show that by utilizing highly sensitive genetic sequencing technologies, tumor-specific TP53 genetic alterations can be identified in the plasma of HNSCC patients upon tumor resection, even at low abundance, and that they are associated with poorer PFS.